First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape

oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]

AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks

Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 2 months

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma / 2 months

Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 4 hrs

DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 36 hrs